ÇѾç´ë±¸¸®º´¿ø ÇãÁØ¿µ ±³¼ö, ¡®Çѱ¹¾ÏÇмúÀç´Ü Çмú»ó¡¯ ¼ö»ó
2020/06/16 10:50 ÀÔ·Â
Æ®À§ÅÍ·Î ±â»çÀü¼Û ÆäÀ̽ººÏÀ¸·Î ±â»çÀü¼Û
¸é¿ªÇ×¾ÏÁ¦ °ü·Ã ºÎÀÛ¿ëÀ» Ä¡·áÇÏ´Â ±Ù°Å Á¦½Ã
ÇѾç´ë±¸¸®º´¿ø ÇãÁØ¿µ ±³¼ö.jpg¡ã ÇãÁØ¿µ ±³¼ö
ÇѾç´ëÇб³±¸¸®º´¿ø Ç÷¾×Á¾¾ç³»°ú ÇãÁØ¿µ ±³¼ö°¡ ´ëÇÑÁ¾¾ç³»°úÇÐȸ¿¡¼­ ÀÓ»ó ¾Ï ¿¬±¸ ºÐ¾ßÀÇ ³í¹®À¸·Î ¡®2020³â Çѱ¹¾ÏÇмúÀç´Ü Çмú»ó¡¯À» ¼ö»óÇß´Ù.
 
Çã ±³¼ö´Â Oncoimmunology (IF=5.33)¿¡ °ÔÀçµÈ 'Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment' ¶ó´Â Á¦¸ñÀÇ ³í¹®À¸·Î À̹ø »óÀ» ¼ö»óÇÏ¿´´Ù.
 
ÀÌ¿Í °ü·Ã Çã ±³¼ö´Â ¡°¸é¿ªÇ×¾ÏÁ¦ Åõ¿© ÀüÈÄ T¸²ÇÁ±¸ÀÇ º¯È­ÆÐÅÏÀ» ÅëÇÏ¿© ¸é¿ªÇ×¾ÏÁ¦ ºÎÀÛ¿ëÀÇ ±âÀüÀ» ¹àÈ÷°íÀÚ ÇÑ ³í¹®À¸·Î, À̹ø ¿¬±¸ °á°ú¸¦ Åä´ë·Î ¸é¿ªÇ×¾ÏÁ¦ °ü·Ã ºÎÀÛ¿ëÀ» Ä¡·áÇÏ´Â ±Ù°Å¸¦ Á¦½ÃÇÏ°íÀÚ ÇÑ´Ù¡±°í ¼Ò°¨À» ¹àÇû´Ù.
 
ÇãÁØ¿µ ±³¼ö´Â ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐÀ» Á¹¾÷ÇÏ°í, °æÈñ´ë ´ëÇпø¿¡¼­ ¼®»ç¿Í ¼º±Õ°ü´ë ´ëÇпø ¹Ú»ç ¼ö·á ¹× »ï¼º¼­¿ïº´¿ø Ç÷¾×Á¾¾ç³»°ú Àӻ󰭻縦 ¼ö·áÇÏ¿´À¸¸ç, ´ëÇѳ»°úÇÐȸ, ´ëÇѾÏÇÐȸ, ´ëÇÑÇ÷¾×ÇÐȸ, ´ëÇÑÁ¾¾ç³»°úÇÐȸ, ´ëÇÑÇ׾Ͽä¹ý¿¬±¸È¸, ¹Ì±¹¾Ï¿¬±¸ÇÐȸ (American Association for Cancer Research, AACR) µî¿¡¼­ È°¹ßÇÑ È°µ¿À» ÇÏ°í ÀÖ´Ù.
[ Á¤Á¾¹Î ±âÀÚ mdilbo@hanmail.net ]
Á¤Á¾¹Î ±âÀÚ ±âÀÚÀÇ ´Ù¸¥ ±â»ç º¸±â
±â»çÁ¦º¸ ¹× º¸µµÀÚ·á news@medicalilbo.com
¢Æ¢Æ ÀÇ·áÀϺ¸ ¢Æ¢Æ(www.medicalilbo.com) - copyright ¨Ï ¢Æ¢Æ ÀÇ·áÀϺ¸ ¢Æ¢Æ. ¹«´ÜÀüÀç & Àç¹èÆ÷ ±ÝÁö
´ñ±Û´Þ±â
  • ¸¹À̺»±â»ç
  • È­Á¦ÀÇ ´º½º

È­Á¦ÀÇ Æ÷Åä

È­Á¦ÀÇ Æ÷Åä´õº¸±â

    È­Á¦Àǵ¿¿µ»ó

    È­Á¦ÀÇ µ¿¿µ»ó
    • ȸ»ç¼Ò°³
    • ±¤°í¾È³»
    • Á¦ÈÞ·±¤°í¹®ÀÇ
    • ±â»çÁ¦º¸
    • Á¤±â±¸µ¶½Åû
    • °í°´¼¾ÅÍ
    • ÀúÀÛ±ÇÁ¤Ã¥
    • ȸ¿ø¾à°ü
    • °³ÀÎÁ¤º¸Ãë±Þ¹æħ
    • À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ
    • RSS
    • ÀÇ·áÀϺ¸ www.medicalilbo.com | ¼³¸³ÀÏ : 2009³â 9¿ù 7ÀÏ | ¥Ø 06653 ¼­¿ï½Ã ¼­Ãʱ¸ ¼­Ãʵ¿ 1589-14 ½Å¼º¿ÀÇǽºÅÚ Bµ¿ 407È£
      »ç¾÷ÀÚµî·Ï¹øÈ£ : 105-07-38362 | µî·Ï¹øÈ£ : ¼­¿ï½Ã ´Ù 09845
      ÀüÈ­ : 02) 333-3739, 363-3730 ±¤°í¹®ÀÇ : 02) 333-3739 | Æѽº 02) 363-3730 |  news@medicalilbo.com
      Copyright ¨Ï 2009 medicalilbo.com All right reserved.
      ¢Æ¢Æ ÀÇ·áÀϺ¸ ¢Æ¢ÆÀÇ ¸ðµç ÄÜÅÙÃ÷(±â»ç)´Â ÀúÀ۱ǹýÀÇ º¸È£¸¦ ¹Þ½À´Ï´Ù. ¹«´Ü ÀüÀç·º¹»ç·¹èÆ÷ µîÀ» ±ÝÇÕ´Ï´Ù.